

# EVGEN PHARMA PLC

Harnessing The Power of Sulforaphane

2021 AGM

# Disclaimer

**THIS PRESENTATION (AS DEFINED BELOW) IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA, JAPAN, NEW ZEALAND AND THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.**

This document and the related verbal presentation (together the "**Presentation**") are for your information only, and are being delivered by Evgen Pharma plc (the "**Company**" or "**Evgen**") which trades on the AIM market of the London Stock Exchange under ticker EVG.

By attending this Presentation, you agree to be bound by the following conditions. Please note that the information in this Presentation has yet to be announced or otherwise made public and some or all of the information in this Presentation or any discussion surrounding the Presentation may constitute inside information relating to the securities of the Company within the meaning of the insider dealing provisions of the Criminal Justice Act 1993 and/or of the EU Market Abuse Regulation (Regulation 596/2014) as it applies in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 ("**MAR**"). By accepting this Presentation the recipient agrees to comply with its obligations under the MAR, including by not making use of any of inside information for the purpose of dealing, or of counselling or procuring any other person to deal, in the securities of the Company. The information and opinions contained in this Presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this Presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this and any errors therein or omissions therefrom.

This document is not an admission document or a prospectus. This document does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefor. This Presentation has not been authorised or approved for the purposes of section 21 of the Financial Services and Markets Act 2000 and therefore it is being delivered for information purposes within (a) the United Kingdom only to persons (i) who have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "**Order**") or are high net worth entities falling within Article 49(2)(a) to (d) of the Order and investment personnel of any of the foregoing (each within the meaning of the Order); and (ii) who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) as it applies in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 ("**Qualified Investors**"); and (iii) to whom the Presentation may otherwise lawfully be communicated; (b) the European Economic Area (the "**EEA**") only to Qualified Investors (all such persons together being referred to as "**Relevant Persons**") and each a "**Relevant Person**"). By accepting this Presentation and not immediately returning it, the recipient represents and warrants that they are a Relevant Person and agrees to be bound by the following conditions. This Presentation is not to be disclosed to any other person or used for any other purpose.

**If you are in any doubt about the contents of this document, you should consult a person authorised under the Financial Services and Markets Act 2000 who specialises in advising on the acquisition of shares and securities of unlisted companies. You should be aware that an investment in the Company involves a high degree of risk and investors should be aware of such risks and should rely on their own examination of the Company and make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser.** Any investment or investment activity to which this document relates is only available to Relevant Persons. Persons of any other description should not rely on this document or act on its contents for any purpose whatsoever and should return it to the Company immediately.

The distribution of this Presentation in certain jurisdictions may be restricted by law, and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. Although reasonable care has been taken to ensure that the facts stated in this Presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this Presentation have not been verified by the Company or any other person. Accordingly no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation and no reliance should be placed on such information or opinions. None of the Company, or any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this Presentation. No part of this Presentation, or the fact of its distribution, should form the basis of or be relied upon in connection with any contract or commitment or investment decision whatsoever.

Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with the Company or its representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the Company or any transaction to be entered into by any member of the Evgen group. No undertaking, representation or warranty, express or implied, is given by the Company, any member of the Evgen group, or any of their respective current or proposed directors, officers, partners, employees, secondees, agents or advisers or any other person as to the accuracy or completeness of the information or as to the opinions contained in this document and no liability is accepted for any such information or opinions. Further, the information in this Presentation is not complete and may be changed. Recipients of this Presentation should each make their own independent evaluation of the information and of the relevance and adequacy of the information in this document and should make such other investigations as they deem necessary.

This Presentation may contain forward-looking statements that reflect the Company's current views and expectations regarding future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "envisages", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "could", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward looking statements. These forward-looking statements include matters that are not historical facts and speak only as of the date of this Presentation. They appear in a number of places throughout this document and include statements regarding the Company and the directors, and the directors' current intentions, beliefs or expectations concerning, amongst other things, to management's strategic vision, aims and objectives, the conduct of clinical trials, the filing dates for product licence applications and the anticipated launch of specified products in various markets, the Company's ability to find partners for the development and commercialisation of its products as well as the terms for such partnerships, anticipated levels of demand for existing products and products in development, the effect of competition, anticipated efficiencies, trends in results of operations, margins, the overall pharmaceutical market and exchange rates, are all forward looking in nature.

# Evgen - A *Clinical Stage* Drug Development Company

Focus on breast cancer, glioma and other cancers, **SFX-01** has **three molecular targets**  
- STAT 3, Nrf2 and SHP2

- Semi-virtual, listed on AIM (LSE: EVG), focus: **cancer and inflammation**
- 275m shares in issue, market cap c.£14m, prior range £27m to £11m
- Developing a new class of pharmaceuticals - based on highly biologically active “sulforaphane” - applications in multiple therapeutic areas based on a network of targets
- Target diseases in cancer and inflammation, each with **high unmet clinical needs**
- Unique platform technology – Sulforadex, stabilises unstable sulforaphane, lead SFX-01
- Strong, **granted IP** covering composition, manufacturing and novel derivatives
- Highly experienced board and management
- Business model: establish proof of concept and partner. **Multiple value inflection points**

# 2020/21 Achievements

- mBC** Promising Phase 2a clinical data. Pre-clinical data from collaboration with University of Manchester and The Christie Hospital suggests SFX-01 may be effective in CDK4/6 resistant patients.
- GLIOMA** Powerful pre-clinical data including significant survival benefit from University of L'Aquila, Italy. *In vitro* data reproduced in patient-derived cells in University of Auckland, New Zealand.
- ONC 3** Encouraging pre-clinical data in JMML cells & AML cells from Oxford University
- PARTNER** Sulforadex technology licence concluded with Juvenescence for non-pharmaceutical applications using naturally derived sulforaphane. \$10.5m in total milestones, \$0.25m received.
- ARDS/COVID** Opportunistic STAR trial was futile, but important clinical data from 133 patients being analysed. Drug exposure and safety database to be significantly expanded.
- FINANCIAL** Position significantly strengthened after £11m placing and open offer Q1 2021; year end cash £11.6m
- PEOPLE** Dr Huw Jones appointed CEO, Oct 2020; Dr Helen Kuhlman, CBO Apr 2021; Dr Glen Clack, CMO May 2021

# Management and Board

Extensive commercial, regulatory, clinical CMC/Manufacturing, business development expertise and a successful commercial track record



**Dr Huw Jones,  
CEO**

Over 30 years' experience of leadership in public and private R&D-based companies within the sector: Chronos Therapeutics, CV Therapeutics, Elan Corp and SB (GSK)



**Richard Moulson,  
CFO**

Chartered accountant with over 20 years experience as CFO for UK quoted and VC-owned companies: Intercytex Group Plc, ReNeuron Group plc and Cobra Therapeutics Ltd



**Dr Helen Kuhlman,  
CBO**

Over 20 years' experience of funding, commercial and R&D roles. Welsh Development Bank, Chronos Therapeutics, Innovate UK, Domantis, CAT



**Dr Glen Clack,  
CMO**

Over 20 years' experience of oncology development, radiation and translational medicine at AZ. Hon Prof at University of Sheffield



**Barry Clare, Chair**  
Former main Board

member of Boots Company plc and Deputy Chairman UHSM Foundation Trust



**Dr Alan Barge, NED**  
Former CMO of ASLAN

Pharmaceuticals, former VP and Head of Oncology and infection at AZ. Venture Partner of Delin Ventures.



**Dr Sue Foden, NED**

Former NED and Chair of the Remuneration Committee at BTG and Vectura Plc. Previously Chair of Bergenbio.



**Susan Clement-Davies, NED**

Over 25 years of capital markets and investment banking experience and former Managing Director of Citigroup and Salomon Smith Barney and Torrey

# Scientific Advisors



**Dr Mary Stuart**  
**Consultant, Breast Cancer Programme**  
Previously Global Clinical Leader/medical Science Director at AZ and CSL at Roche



**Dr Sacha Howell**  
Consultant Medical Oncologist at Christie Foundation Trust  
Clinical Senior Lecturer at Division of Cancer Sciences, Manchester University



**Professor Rob Clark**  
Professor of Breast Biology, University of Manchester



**Professor Anthony Chalmers**  
Chair of Clinical Oncology at University of Glasgow: principal interest is in Glioblastoma



**Professor Bruce Baguley**  
Distinguished Professor, University of Auckland



**Dr Euphemia Leung**  
Snr Research Fellow, University of Auckland



**Professor Phillip Eaton**  
Professor Cardiovascular Biochemistry, Queen Mary University of London



**Professor Claudio Festuccia**  
Professor of Applied Clinical Studies at L'Aquila University



**Professor Albena Dinkova-Kostova**  
Professor of Chemical Biology, Dundee and Adjunct Professor at Johns Hopkins University

# Pipeline Progress, Benchmark Value, Plan SFX-01

Discovery	Pre-clinical POC	Phase 1	Phase 2a	Partnering Market average*	FY 2021/22 Milestones
ER+ve Breast Cancer				<b>\$19m up front, \$144m total</b>	In vivo pre-clinical data in CDK 4/6 resistance. Phase 2b design.
Glioma				<b>\$11m up front, \$90m +equity</b>	Orphan drug approval Q3/4, IND submission Q4, Phase 2 clinical study start.
Onc 3					Indication selection, non-dilutive funding.
Opportunistic					Pre-clinical in vivo experiments start Q3, completed Q4.



# SFX-01 Can Be Life-changing

- Diagnosed age 40 ER+ Her2- early Breast Cancer
- Received surgery, chemotherapy and tamoxifen
- After 5 years diagnosed with pleural nodules
- Enrolled into Phase 2a trial May 2017 – tamoxifen + SFX-01
- Objective response to treatment, very well tolerated, able to continue her life caring for her 2 young children and husband with head and neck cancer
- Entered the extended use programme and had Stable Disease for a total of 597 days, including tumour shrinkage of 63% from baseline

May 2017



June 2018




5 patients remained progression free after 1 year of treatment with SFX-01 + ET

# Glioblastoma (GBM)

- Very poor life expectancy, average time to death after diagnosis 14 months, 5% five-year survival. Current treatments include surgical resection, radiotherapy and chemotherapy, frequent relapses.
- In US GBM accounts for 57% of gliomas, with circa 11,500 diagnosed per annum\*
- *In vitro* studies with patient-derived cell lines showed dose-dependent reduction in proliferation and migration.
- In orthotopic xenograft models, treatment with SFX-01 increased disease-free survival and lengthened tumour progression times, an effect that is synergistic with radiotherapy.
- *In vitro* data from Aquila has been reproduced at University of Auckland in cells generated from freshly extracted patient GBM tissue.

\*Source: Central Brain Tumor Registry of the United States

# Dr Euphemia Leung, Prof Bruce Baguley –University of Auckland: low passage glioma (and other) cell lines



$\alpha$  cyclodextrin control – no effect

# Glioblastoma next steps

- Further *in vivo* work at a CRO to build upon the subcutaneous GBM tumour model experiments conducted by Aquila.
- Orphan Drug Application submitted to FDA
- Plans for a Phase II GBM clinical trial with an adaptive design are progressing. IND being prepared for submission to the US Food and Drug Administration in Q4/2021.
- Trial scheduled to commence in H1/2022

# Summary

- Semi-virtual, listed on AIM (LSE: EVG), focus: **cancer and inflammation**
- **Granted IP on SFX-01 and analogues**
- Exciting pre-clinical data in multiple cancers, Glioblastoma, BC, JMML
- Positive Phase 2 clinical data in breast cancer
- Multiple value inflection points, **licensing deals in our therapy areas range from \$90m to \$150m with \$11m to \$19m up front and double digit royalties**
- Highly experienced board and management
- Non-pharma partnership – market launch 2023

# Evgen Pharma plc

[www.evgen.com](http://www.evgen.com)

*Contact:*

*[enquiries@evgen.com](mailto:enquiries@evgen.com)*

*Dr Huw Jones, CEO*

*Richard Moulson, CFO*

*finncap*

*Geoff Nash*

*[gnash@finncap.com](mailto:gnash@finncap.com)*

*Edward Whiley*

*[ewhiley@finncap.com](mailto:ewhiley@finncap.com)*

